Sign in Register

Drug class

Substance P-Neurokinin 1 (NK1) Receptor Antagonists

Substance P/neurokinin 1 (NK1) receptor antagonists are an established pharmacologic class of antiemetic medications that competitively bind to NK1 receptors in the central and peripheral nervous systems. Read more about Substance P-Neurokinin 1 (NK1) Receptor Antagonists

47 drugs in this class 30 manufacturers

Related classes & indications

Proton Pump InhibitorsGastrointestinal · 219 prescription drugs Histamine-2 Receptor Antagonists (H2 Antagonists)Gastrointestinal · 78 prescription drugs Prevention Of Post-Operative Nausea And VomitingTop indication · 290 prescription drugs

Showing 28–36 of 47 drugs

Sort

FOSAPREPITANT DIMEGLUMINE

ANTIEMETIC · PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

EUGIA US LLC

FOSAPREPITANT DIMEGLUMINE

ANTIEMETIC · PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

APOTEX CORP

FOSAPREPITANT DIMEGLUMINE

ANTIEMETIC · PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

BLUEPOINT LABOR

FOSAPREPITANT DIMEGLUMINE

ANTIEMETIC · PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

ATHENEX PHARMAC

FOSAPREPITANT DIMEGLUMINE

ANTIEMETIC · PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

BE PHARMACEUTIC

FOSAPREPITANT DIMEGLUMINE

ANTIEMETIC · PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

NOVADOZ PHARMAC

FOSAPREPITANT DIMEGLUMINE

ANTIEMETIC · PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

HEPALINK USA, I

FOSAPREPITANT DIMEGLUMINE

ANTIEMETIC · PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

AVENACY, INC

FOSAPREPITANT DIMEGLUMINE

ANTIEMETIC · PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

MYLAN INSTITUTI

Filter & compare in the drug finder → Opens the drug finder with Substance P-Neurokinin 1 (NK1) Receptor Antagonists preselected. Add indication or manufacturer filters there.

About Substance P-Neurokinin 1 (NK1) Receptor Antagonists.

Substance P/neurokinin 1 (NK1) receptor antagonists are an established pharmacologic class of antiemetic medications that competitively bind to NK1 receptors in the central and peripheral nervous systems.

By selectively blocking endogenous substance P from activating these neuroreceptors in key brainstem emetic centers, such as the area postrema and the nucleus tractus solitarius, they inhibit signaling pathways that trigger the vomiting reflex.

Clinically, these agents are primarily indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with emetogenic cancer therapies, as well as for the prevention of postoperative nausea and vomiting.

fda.gov
Substance P/neurokinin 1 (NK1) receptor antagonists are an established pharmacologic class of antiemetic medications that competitively bind to NK1 receptors in the central and peripheral nervous systems Clinically, these agents are primarily indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with emetogenic cancer therapies, as well as for the prevention of postoperative nausea and vomiting
fda.gov
Substance P/neurokinin 1 (NK1) receptor antagonists are an established pharmacologic class of antiemetic medications that competitively bind to NK1 receptors in the central and peripheral nervous systems
fda.gov
Substance P/neurokinin 1 (NK1) receptor antagonists are an established pharmacologic class of antiemetic medications that competitively bind to NK1 receptors in the central and peripheral nervous systems
fda.gov
Substance P/neurokinin 1 (NK1) receptor antagonists are an established pharmacologic class of antiemetic medications that competitively bind to NK1 receptors in the central and peripheral nervous systems
fda.gov
By selectively blocking endogenous substance P from activating these neuroreceptors in key brainstem emetic centers, such as the area postrema and the nucleus tractus solitarius, they inhibit signaling pathways that trigger the vomiting reflex
nv.gov
By selectively blocking endogenous substance P from activating these neuroreceptors in key brainstem emetic centers, such as the area postrema and the nucleus tractus solitarius, they inhibit signaling pathways that trigger the vomiting reflex
fda.gov
Clinically, these agents are primarily indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with emetogenic cancer therapies, as well as for the prevention of postoperative nausea and vomiting
fda.gov
Clinically, these agents are primarily indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with emetogenic cancer therapies, as well as for the prevention of postoperative nausea and vomiting